DNMDP is a phosphodiesterase 3A inhibitor with clear cell-selective cytotoxicity. DNMDP binding to PDE3A promotes interaction between PDE3A and Schlafen 12.

DNMDP (0-1000 μM; 48 hours) displays clear cell-selective cytotoxicity. HeLa cells undergo apoptosis upon DNMDP treatment, indicates by caspase activity detected by a caspase-sensitive luciferase assay and by PARP cleavage. DNMDP (100 nM) specifically inhibits both PDE3A and PDE3B, but it weakly inhibits PDE10. It also had little or no detectable effect on other phosphodiesterases.